Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2842 Transformation to High Grade 3 (G3) Neuroendocrine Neoplasia (NEN) – Molecular Imaging, Pathologic Features and Patient Outcomes

Introduction: Transformation of lower grade to Grade 3 (G3) NEN potentially impacts prognosis & treatment options.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Kong G, Callahan J, Prall O, Michael M, Hicks R,

Keywords: Transformation, G3 NEN, PET imaging, mutation, PRRT, prognosis,

#1784 Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL)

Introduction: Treatment options for metastatic PCC/PGL and related hypertension (HTN) are limited. Experiences in PRRT suggest favourable disease control, but lack of data on HTN response.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: kong G

Authors: Kong G, Grozinsky-Glasberg S, Callahan J, Hofman M, Meirovitz A,

Keywords: PRRT,

#1391 Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) - A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT)

Introduction: Bulky disease from NET is an adverse prognostic factor for response to 177Lu-DOTA-octreotate (LuTate) PRCRT. 90Y-DOTA-octreotate (YTate) has more penetrating particulate emissions.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Kong G, Callahan J, Hofman M, Pattison D, Akhurst T,

Keywords: PRRT, Y-90,

#1212 Circulating Gene Transcript Analysis of Pancreatic NETs

Introduction: PNETs are aggressive with poor survival. Therapeutic agents are available but efficacy determination is limited by imaging insensitivity and the lack of effective blood biomarkers.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Kidd M

Authors: Kidd M, Modlin I, Drozdov I, Alaimo D, Callahan S,

Keywords: PNET, NETest, PCR,

#1195 Neuroendocrine Gene Transcript Analysis of Blood Identifies Stable or Progressive NET Disease Treated with Somatostatin Analogs.

Introduction: An issue in NET management is defining stable or progressive disease and effective treatment. An alternative to RECIST criteria is a sensitive, reproducible blood biomarker test. Somatostatin analogs (SSA) are a chief therapy but efficacy is subjective and based on symptom control and imaging.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Alaimo D, Callahan S, Lepensky C, Jonzzon S, Teixeira N,

Keywords: Biomarker, SSA,

Abstract Submissions in 2022

Abstract submissions for 2022 will open in September 2021!

 

The 19th Annual ENETS Conference in 2022 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.